French Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD)
← catalyst calendarNCT06837454 · readout in 267 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
600estimated
Sites
62
Country
France
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-04 | actual | When the study began enrolling |
| Primary completion | 2027-05-13 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-05-13 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atopic Dermatitis
Primary outcomes
what the primary-completion date above is the date OFPrevious and Current Treatments for Atopic Dermatitis (AD)
measured Baseline, month 6 and month 12
Atopic Comorbidities: Previous and Current Therapeutic Management
measured Baseline, month 6 and month 12
Change from Baseline in Drug Survival for Systemic Treatments for AD by Name and Dose
measured Baseline, month 6 and month 12
Compliance for AD Treatments
measured Baseline, month 6 and month 12
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed